证券代码：300572 证券简称：安车检测 深圳市安车检测股份有限公司投资者关系活动记录表 编号：20250509 | 投资者关系活动 | □特定对象调研 □分析师会议 | | --- | --- | | 类别 | □媒体采访 ☑业绩说明会 | | | □新闻发布会 □路演活动 | | | □现场参观 | | | □其他 （请文字说明其他活动内容） | | 参与单位名称及 | 网上投资者 | | 人员姓名 | | | 时间 | 2025 年 5 月 9 日 15:00-16:00 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 采用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 公司董事长贺宪宁先生；副总经理、财务总监兼董事会秘书李云 | | 员姓名 | 彬先生；独立董事杨文先生 | | | 为便于广大投资者更深入、全面地了解公司发展战略、生产 经营等情况，公司于全景网举行了 2024 年度网上业绩说明会。本 | | | 次说明会采用网络远程方式召开。 | | | 1、公司新的一年有什么新的发展计划吗？ | | | 答：您好，感谢您对公司的 ...

导读： 国产无损检测设备厂商2024业绩亮眼，ACCSI2025第二届无损检测技术创新发展论坛将再掀技术风暴！ 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 在全球制造业智能化转型的浪潮中，中国无损检测产业正迎来历史性跨越。2 0 2 4年，以奕瑞科技、日联科技为代表的国产龙头企业不仅交出了 亮眼的成绩单，更在多个技术领域实现从"跟跑"到"领跑"的质变。值此产业升级关键节点，"ACCSI 2 0 2 5第二届无损检测技术创新发展论坛"将 于2 0 2 5年5月1 3日在上海隆重召开，汇聚产学研用各方力量，共谋行业发展新篇章。 国产崛起：2 0 2 4年度成绩单彰显硬实力 高端成像领域突破者 奕 瑞 科 技 研 发 投 入 超 3 亿 元 ， 其 光 子 计 数 探 测 器 技 术 达 到 国 际 领 先 水 平 ， 成 功 打 破 欧 美 在 医 疗 CT 探 测 器 领 域 长 达 2 0 年 的 垄 断 ； 最 新 推 出 的 Me r c u 1 7 1 7XN动静结合系列探测器已进入西门子、GE的供应链体系。 三英精密净利 ...

日前，由生态环境部、最高人民法院、最高人民检察院、国家发展和改革委员会等9部门联合编制的《关于进一步优化机动车环境监 管的意见》（以下简称《意见》）正式发布，对机动车、特别是货车排放问题的监管做出了更加严格的规定。 《意见》明确，将试行货车差异化定期排放检验制度。对于总质量3.5吨以上柴油货车，配置远程排放管理车载终端并按要求报送相 关数据；将货车抽查纳入日常监管和执法检查计划。重点检查不正常使用污染控制装置、不正常运行车载排放诊断系统、擅自改装污染控 制装置、冒黑烟等问题；强化机动车排放检验机构准入管理，对违法情节严重的机动车排放检验机构将依法取消检验资格；加快修订机动 车国六排放标准；研究制订在用车OBD检测方法等。 01 推动合规达标和污染减排 《意见》的出台是对我国机动车污染治理短板的系统性回应，通过科技赋能、全链条监管和跨部门协同，推动环境监管从"被动应 对"转向"主动预防"。相较于以往政策，其核心突破在于整合技术手段与制度设计，构建起覆盖更广、责任更严、协同更强的治理体系。 今年2月24日，在生态环境部举行的例行新闻发布会上，生态环境部大气环境司司长李天威表示，"十四五"以来，我国大气污染防治 形 ...

□ 本报记者仇惠栋万小珍 通讯员冯徐波 这个"五一"假期，常州天宁区"热力值"拉满。10家景区景点迎来游客111.82万人次，常州万象城、天宁 吾悦广场、九洲新世界等商业体单日客流均创历史新高……放眼更大的"坐标系"，老城区正澎湃新动 能，2024年地区生产总值迈上千亿元台阶，全国市辖区高质量发展百强榜攀升至第37位。 今年初，省政府批复的常州市天宁区国土空间总体规划，明确其"常州城区文商中心、城乡融合典范、 产城融合高地"发展定位。"作为常州主城区，我们要主动对标'挑大梁的着力点'，坚持优服务、促消费 挑起大梁，提产业、引项目紧紧跟上。"天宁区委书记、区长张凯奇表示，天宁要立足自身优势，构建 先进制造业和现代服务业"双轮驱动"现代产业格局，既重视总量扩张的物理变化，更注重动能转换的化 学反应，以高质量发展的"稳"与"进"，托举起"千亿之区"的"质"与"量"。 一张票根串起一条消费链 4月20日，2025常州天宁大运河半程马拉松鸣枪开跑。万名跑友持参赛号码牌，可享受20余家商户提供 的60余项专属优惠。 4月下旬，林忆莲常州演唱会期间，奥体中心周边酒店爆满，餐饮店翻台率翻倍，商场夜间客流激增。 歌迷们手持票根 ...

Core Viewpoint - The company reported a revenue of 3.207 billion yuan for 2024, representing a year-on-year growth of 11.01%, and a net profit attributable to shareholders of 352 million yuan, up 76.59% year-on-year [1] Financial Performance - For the entire year of 2024, the gross margin and net margin were 47.21% and 11.21%, respectively, showing an increase of 4.93 percentage points and 4.07 percentage points year-on-year [2] - In Q4 2024, the company achieved a revenue of 1.047 billion yuan, a year-on-year increase of 13.11% and a quarter-on-quarter increase of 28.32%, with a net profit of 163 million yuan, up 145.18% year-on-year and 49.75% quarter-on-quarter [2] - The gross margin and net margin for Q4 2024 were 52.73% and 16.7%, respectively, reflecting a year-on-year increase of 10.52 and 8.17 percentage points [2] - For Q1 2025, the company reported a revenue of 618 million yuan, a year-on-year increase of 5.16% but a quarter-on-quarter decrease of 40.98%, with a net profit of 5 million yuan, up 302.86% year-on-year but down 97.05% quarter-on-quarter [2] Business Segmentation - The company generated revenue from various segments in 2024: measurement (750 million yuan), reliability (780 million yuan), life sciences (500 million yuan), electromagnetic compatibility (360 million yuan), integrated circuits (260 million yuan), and EHS evaluation (180 million yuan), with year-on-year growth rates of +3.8%, +17.5%, +2.7%, +10.2%, +26.3%, and +2.6%, respectively [3] - The gross margins for these segments were 50.5%, 50.9%, 39.8%, 54.9%, 45.2%, and 38.0%, with year-on-year changes of +2.4, +7.4, +8.8, +4.0, +4.3, and -6.49 percentage points [3] - The company focuses on emerging industries, with over 80% of its business coming from sectors such as special industries, automotive, new energy, integrated circuits, commercial aerospace, communication, low-altitude economy, and artificial intelligence [3] Shareholder Returns - The company conducted active market value management, distributing a total dividend of 224 million yuan for the year, with a mid-year dividend of 140 million yuan and a total of 614 million yuan in dividends and share buybacks, representing 174% of the annual net profit attributable to shareholders [4] - The projected net profits for 2025 to 2027 are 420 million yuan, 510 million yuan, and 600 million yuan, reflecting year-on-year growth rates of +20%, +20%, and +18%, respectively [4]

Core Insights - A breakthrough technology has been developed by the Institute of Software Research, Chinese Academy of Sciences, in collaboration with the First Hospital of Hebei Medical University, which efficiently identifies emotional disorders such as anxiety and depression through eye movement analysis during natural viewing of table tennis matches [1][2] - This technology offers a non-invasive and convenient new solution for mental health monitoring, with results published in the prestigious journal "Frontiers in Neurology" [1] Summary by Sections Technology Development - The research team utilized dynamic sports videos, specifically table tennis matches, as natural visual stimuli combined with virtual reality (VR) technology and machine learning algorithms to collect eye movement data without the need for active participation from subjects [1] - The study involved 25 participants, including 12 emotional disorder patients and 13 healthy controls, who watched table tennis and tennis match videos while their eye movement characteristics were recorded using the EyeKnow eye-tracking system [1] Research Findings - Significant testing and machine learning analysis revealed that 11 eye movement features from the table tennis videos effectively distinguished emotional disorders, with "Gaze Entropy" achieving an accuracy rate of 88% [2] - A decision tree model trained on all significant features reached an overall accuracy of 92% and an area under the ROC curve of 0.94, outperforming traditional assessment scales [2] - The tennis video showed weaker distinguishing effects due to lower familiarity among participants, but some indicators still demonstrated potential for adaptation to new content as a biological marker for emotional disorders [2] Future Applications - The core advantage of this technology lies in its "natural and unobtrusive" nature, requiring no active cooperation or professional guidance, allowing for detection simply through watching everyday videos [2] - Future integration into smart TVs and mobile devices is anticipated, enabling at-home mental health monitoring [2] - The research leader, Professor Tian Feng, emphasized that this method integrates disease screening into daily life, providing a low-cost and highly compliant long-term monitoring tool, particularly useful for tracking medication effects and relapse warnings [2]

证券代码：300887 证券简称：谱尼测试 A：主要措施包括： 1、削减盈利能力较弱的建材、无损、能力验证、日消等业务板块，内 部整合食品、环境、医学实验室产能；基于公司内部资源整合，在资产负 债表日,对存在减值迹象的长期资产进行减值测试并确认减值损失。 2、加强应收账款管理、调整优化客户结构以及加强信用管理，对应收 账款等进行减值测试并确认减值损失。 谱尼测试集团股份有限公司投资者关系活动记录表 编号：2025-001 | | □特定对象调研 分析师会议 | | --- | --- | | 投资者关系活动 | □媒体采访 ☑业绩说明会 | | 类别 | □新闻发布会  路演活动 | | | 现场参观 | | |  其他（电话会议） | | 活动参与人员 | 详见附件 | | 时间 | 2025 年 4 月 22 日-5 月 8 日 | | 地点 | 电话会议、网络业绩说明会 | | 上市公司接待 | 董事长 宋薇女士 | | 人员姓名 | 董事、董事会秘书 李小冬先生 | | | 副总、财务负责人 吕琦先生 | | | 一、介绍公司 2024 年度和 25 年一季度业绩情况 | | | 公司 202 ...

Core Viewpoint - The company is optimistic about the future development prospects of Lihong Testing (01586) due to the dual support of AI and overseas business, maintaining a target price of HKD 3.18 per share, with corresponding PE ratios of 19.8x, 17.4x, and 15.2x for 2025, 2026, and 2027 respectively, and a "Buy" rating [1] Group 1: Financial Performance - The company's performance met expectations, with revenue growth of 12.9% to HKD 1.263 billion [2] - The company achieved a net profit attributable to shareholders of HKD 82.725 million, a year-on-year increase of 3.4% [2] - The company is actively expanding its overseas network to build a global service network while maintaining steady growth in traditional energy bulk business [2] Group 2: Overseas Business Development - Revenue from the Greater China region reached HKD 696 million, a 7% year-on-year increase, driven by stable domestic demand for consumer product testing [3] - Overseas revenue amounted to HKD 568 million, up 21.3% year-on-year, benefiting from improved overseas network and growth in Singapore's oil testing business [3] - The overseas business team performed excellently, with overseas revenue accounting for 45% of total revenue [3] Group 3: AI Investment and Efficiency - The company has deployed its self-developed "Lihong AI System," achieving deep integration of AI models with core energy testing business [4] - Plans are in place to complete global deployment of the AI system by 2025, with continuous breakthroughs in cross-border inspection AI recognition systems and carbon emission accounting modules [4] - AI empowerment is expected to enhance testing efficiency and provide more customized services, increasing product competitiveness and customer loyalty [4] Group 4: Shareholder Returns - The company has initiated a share buyback plan based on market conditions and strategic considerations, starting from December 13 [5] - The buyback initiative is expected to provide continuous returns to shareholders [5]

Group 1 - The core viewpoint of the articles highlights the performance and market position of Berry Genomics, noting its recent stock price increase and market capitalization [1] - As of March 31, 2025, Berry Genomics has 63,808 shareholders, an increase of 19,482 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares [1] - The company specializes in gene testing services and related equipment and reagent sales, leveraging high-throughput sequencing technology [1] - Berry Genomics has established a leadership position in genetics through its comprehensive "product + service" solutions for hospitals and medical laboratories, capitalizing on its first-mover advantage in the NIPT project [1] - The company has developed the cSMART liquid biopsy technology, which has received domestic and international patents, solidifying its leading position in oncology [1] Group 2 - The latest financial report for the first quarter of 2025 shows Berry Genomics achieved a revenue of 218 million yuan, a year-on-year decrease of 22.08%, and a net loss of approximately 6.46 million yuan, a year-on-year decline of 178.47%, with a gross profit margin of 49.48% [1] - The company's price-to-earnings (P/E) ratio is reported at -22.14 (TTM) and -23.83 (static), with a price-to-book (P/B) ratio of 2.75, and a total market value of 4.585 billion yuan [2] - The industry average P/E ratio is significantly higher at 49.20 (TTM) and 47.65 (static), with an industry median P/B ratio of 2.41 [2]

佛山市南华仪器股份有限公司投资者关系活动记录表 编号：NH/IR2025-01 证券代码：300417 证券简称：南华仪器 | 设备海外市场业务拓展，满足客户需求。 | | --- | | 3、 你们行业本期整体业绩怎么样？你们跟其他公司比如何？ | | 答：2022 年 9 月，公安部、市场监管总局、生态环境部、交 | | 通运输部联合印发《关于深化机动车检验制度改革优化车检服务 | | 工作的意见》，该措施进一步放宽机动车强制检测标准，机动车 | | 检测频次、检测数量存在一定程度的下降。公司所处的机动车检 | | 测行业的相关产品需求有所减少，对本公司和其它公司业绩增长 | | 均造成一定困难。随着时间推移，政策调整带来的影响逐渐减少， | | 新能源汽车检测的逐步实施以及行业规范管理的日益完善，行业 | | 将迎来新的发展阶段。 | | 4、 行业以后的发展前景怎样? | | 答：目前机动车检测行业的相关产品需求短期有所减少，但 | | 随着时间推移，从长期来看，相关政策调整带来的影响逐渐减少， | | 新能源汽车检测的逐步实施以及行业规范管理的日益完善，行业 | | 将迎来新的发展阶段。 | | | ...